Cargando…
Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
BACKGROUND: A thorough understanding of a patient’s inflammatory response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection is crucial to discerning the associated, underlying immunological processes and to the selection and implementation of treatment strategies. Defining pe...
Autores principales: | Sims, Jonathan T., Poorbaugh, Josh, Chang, Ching-Yun, Holzer, Timothy R., Zhang, Lin, Engle, Sarah M., Beasley, Stephanie, Doman, Thompson N., Naughton, Lynn, Higgs, Richard E., Kallewaard, Nicole, Benschop, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931785/ https://www.ncbi.nlm.nih.gov/pubmed/35303909 http://dx.doi.org/10.1186/s12967-022-03345-3 |
Ejemplares similares
-
The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
por: Benschop, Robert J., et al.
Publicado: (2022) -
Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021) -
First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19
por: Chen, Peter, et al.
Publicado: (2021) -
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021) -
Asystole During Nasopharyngeal Swab: Is COVID-19 to Blame?
por: Madanat, Luai, et al.
Publicado: (2021)